WXXWY:OTCMKTS
Wuxi Biologics Cayman ADR
US$ 12.56
arrow_upward
+0.48%(+0.060) Siku 1
16 Okt, 16:00:00 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya WXXWY...
Fungua
US$ 12.29
Juu
US$ 12.56
Chini
US$ 12.20
Mtaji wa soko
198.43B
Wastani wa kiasi cha mauzo
elfu 61.89
Kiasi cha mauzo ya hisa
elfu 110.85
Juu kwa wiki 52
US$ 14.80
Chini kwa wiki 52
US$ 7.30
Beta
0.01
Hisa za wawekezaji
2.06B
Idadi ya wafanyakazi
elfu 15
Fungua
US$ 12.29
Juu
US$ 12.56
Chini
US$ 12.20
Mtaji wa soko
198.43B
Wastani wa kiasi cha mauzo
elfu 61.89
Kiasi cha mauzo ya hisa
elfu 110.85
Juu kwa wiki 52
US$ 14.80
Chini kwa wiki 52
US$ 7.30
Beta
0.01
Hisa za wawekezaji
2.06B
Idadi ya wafanyakazi
elfu 15
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Macau Business
·
dakika 49 zilizopita
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight
Simply Wall Street
·
saa 1 iliyopita
Meta (META) Faces Fresh Privacy Scrutiny Over AI Smart Glasses
Bloomberg.com
·
saa 10 zilizopita
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
Yahoo Finance
·
saa 23 zilizopita
Michael Burry Warns of a Stock Market ‘Supervolcano’
Wasifu
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Kuhusu Wuxi Biologics Cayman ADR
Afisa Mkuu Mtendaji (CEO)Zhisheng Chen
Wafanyakazielfu 14.7
Lilianzishwa2010
Makao makuu-
Sekta-
Tovutiwuxibiologics.com